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Burning mouth syndrome (BMS) is an intraoral burning
or dysaesthetic sensation that recurs daily for more than 2
hours per day over more than 3 months in the absence of
any clinically evident causative lesions (International Head-
ache Society, 2018). The neuropathic origin of this condition
has been reported in some studies, while others have demon-
strated the involvement of psychogenic factors (Galli et al.,
2017 ; Jaaskelainen, 2018). The treatment of BMS is com-
plex and varies from the use of topical agents like alpha−
lipoic acid and capsaicin, to the ingestion of anti−anxiety
and anti−depressant drugs ; in addition, cognitive behavioral
therapy has been employed for patients with BMS (de Souza
et al., 2018 ; Matsuoka et al., 2017). Studies regarding the
judicious use of anti−anxiety and anti−depressant drugs on a
case to case basis in patients with BMS are limited (Kremer
et al., 2018 ; McMillan et al., 2016). Herein, we present 4
patients with BMS treated with anti−anxiety and anti−de-
pressant drugs.
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Case 1 (Use of ethyl loflazepate and milnacipran)
A 78−year−old female visited our clinic with a chief com-
plaint of dull pain in the tongue that began a few months
ago. All the secondary causes of burning sensation were
ruled out. A psychological assessment test revealed mild
anxiety. The pain intensity on the Visual Analog Scale
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Burning mouth syndrome (BMS) is an intraoral burn-
ing or dysaesthetic sensation recurring daily for more
than 2 hours per day over more than 3 months without
the presence of any clinically evident causative lesions.
It occurs predominantly in females during the peri− or
post − menopausal period. The etiopathogenesis and
treatment of BMS are complex due to its neuropathic
and psychological origin. There is no specific treatment
protocol for patients with BMS. Anti−anxiety and anti−
depressant drugs have been found to be effective in re-
ducing the symptoms of BMS ; however, the appropri-
ate choice of these drugs varies from case to case.
Herein, we present a case series of 4 patients with
BMS, who received various types of anti−anxiety and
anti−depressant medications based on their symptoms.
The combination of ethyl loflazepate and milnacipran
was effective in case 1 patient. The case 2 patient could
not tolerate milnacipran well and was substituted by
amitriptyline which reduced pain. The case 3 patient
tolerated milnacipran well but was not effective in re-
ducing pain and was substituted by amitriptyline. The
case 4 patient did not respond well to various combina-
tions of drug initially but felt comfortable after combi-
nation therapy with ethyl loflazepate, venlafaxine and
mirtazapine. This report also discusses the rationale be-
hind the use of these drugs.
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(VAS) was 70. An initial stage of candidiasis was suspected,
and topical application of Amphotericin B (4 ml/day) was
prescribed. After a follow−up period of 1 week, the symp-
toms did not improve and a diagnosis of BMS was reached.
An anti−anxiety drug, ethyl loflazepate (0.5 mg/day), was
prescribed for the patient. After 2 months of treatment with
the drug, the pain had reduced and the VAS score was low-
ered to 20. The same medication was continued for another
2 months with no change in pain intensity. A serotonin no-
repinephrine reuptake inhibitor (SNRI), milnacipran (12.5
mg/day) was added to the treatment regime ; the dose was
increased to 25 and 50 mg/day during the next 2 months
follow−up after reviewing the symptoms. After 6 months,
the pain had reduced and the VAS score was further low-
ered to 10. After another 6 months, the pain had almost dis-
appeared and was limited to a few hours in a month. The
patient is on regular follow−up and planning to stop the
medication gradually.
Case 2 (milnacipran intolerance)
A 53−year−old Japanese female was referred to the De-
partment of Oral Medicine at our university hospital with a
chief complaint of burning sensation on the tongue. The
dental history revealed that she was treated for temporoman-
dibular disorders (TMD) a year ago and the TMD pain was
improving. She complained of generalized burning sensation
in the tongue for the past 4 months. The burning sensation
was asymptomatic in the morning but gradually increased
during the day. She also complained that she did not know
where to rest the tongue in the oral cavity. A psychological
assessment test revealed mild anxiety, and a VAS score of
80. A diagnosis of BMS was established after the secondary
causes of burning mouth were ruled out. Ethyl loflazepate (1
mg/day) was prescribed, and the patient was asked to pre-
sent at the department after 2 weeks. On her second visit,
the patient reported that she was feeling better, and pre-
sented with a VAS score of 50. The same medication was
continued for about 3 months with a follow − up every
month. After 3 months, the symptoms had improved consid-
erably, although they persisted when the patient was
stressed. The VAS score during this period was 25. Subse-
quently, 12.5 mg/day of milnacipran was prescribed to the
patient. However, the following week she complained of in-
creased heart rate and blood pressure after taking the drug,
and was advised to stop taking the medication. A tricyclic
anti−depressant (TCA), amitriptyline (10 mg/day) was pre-
scribed instead. The dosage of the new drug was gradually
increased to 20 mg/day and then to 30 mg/day within the
next 2 months. After 12 months of treatment, the VAS score
was lowered to 5, and the BMS was considerably lower than
the tolerance level (limited to 1−2 hours/day). Currently, af-
ter 16 months of treatment, the burning sensation is limited
to a few days/month, and we are considering decreasing the
amitriptyline dose gradually.
Case 3 (substitution of milnacipran with amitriptyline)
A 72−year−old Japanese female visited the Department of
Oral Medicine of our university hospital with a chief com-
plaint of burning sensation on left side of the tongue for the
past few months. Her personal history revealed that she was
very active physically and kept herself engaged in sports
most of the time. However, the psychological assessment
test revealed mild anxiety. The VAS score was measured at
90. After ruling out the secondary causes of the symptoms, a
diagnosis of BMS was established. Ethyl loflazepate (1 mg/
day) was started, and a reduction in symptoms as well as
VAS score (54) was noted after 2 weeks of follow−up. The
patient complained of disturbed sleep, so triazolam (0.25 mg
/day) was added to the treatment regime for a month. After
2 months of treatment the VAS score was 35. Subsequently,
milnacipran (12.5 mg/day) was also prescribed to the pa-
tient, and the dose was increased to 25 mg/day the following
week after reviewing the symptoms. However, 5 months
later, the VAS score remained at 30 ; thus, the patient was
asked to take amitriptyline (10 mg/day) , instead of mil-
nacipran, with a gradual increased in the dose to 30 mg/day
over the next 2 months. After 10 months of treatment, the
VAS score was reduced to 10, and another 16 months later,
the VAS score was limited to 5. The patient was feeling
much better, and plans to taper the dose of amitriptyline.
Case 4 (combination of ethyl loflazepate, venlafaxine, and
mirtazapine)
A 61−year−old Japanese female visited to our department
4 years back with a chief complaint of burning sensation in
the tongue for the past few months. Psychological assess-
ment revealed mild anxiety, and the VAS score was 76. The
patient showed no significant improvement in symptoms af-
ter a month of ethyl loflazepate (1 mg/day) treatment. After
discontinuing the treatment at our hospital for 2 years, the
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patient returned with a complaint that her pain had increased
(VAS score, 80). After considering her drug history and du-
ration of pain, venlafaxine (SNRI ; 37.5 mg/day) and ami-
triptyline (10 mg/day) were prescribed, and the patient was
advised a weekly follow−up. After 2 months, the pain had
subsided and the VAS score was lowered to 5. However,
due to a complaint of sticky saliva in the oral cavity, ethyl
loflazepate (1 mg/day) was added to the treatment regime. A
month later, the pain had increased (VAS score, 30). The
dose of amitriptyline was increased to 20 mg/day. After 2
months follow−up, the patient complained of increased pain
(VAS score, 50) and dry mouth ; therefore, amitriptyline was
stopped and a selective serotonin reuptake inhibitor (SSRI),
sertraline (25 mg/day) was started. However, the patient
complained of nausea during the next follow−up (1 month)
and requested to stop sertraline, and indicated that the com-
bination of venlafaxine, ethyl loflazepate, and amitriptyline
worked best for her. The amitriptyline could not be started
again because of the occurrence of dry mouth. Thus, mir-
tazapine (15 mg/day), a noradrenergic and specific seroton-
ergic anti−depressant (NaSSA) was prescribed. The patient
felt comfortable during the next appointment and presented
with a VAS score of 5. A maxillary and mandibular splint
was also prescribed for symptomatic treatment. The patient
is on constant follow−up and doing well.
??????????
BMS is a diagnosis of exclusion, where a diagnosis is
reached after all the secondary causes of burning sensation
have been excluded. The etiopathogenesis of BMS is com-
plex owing to the two schools of thought with regard to the
factors involved ; neuropathic and psychogenic. The nature
of chronic pain in BMS resembles the symptoms of neuro-
pathic pain and various studies have provided evidence of
the neuropathic origin of this condition (Jaaskelainen, 2018).
However, the role of psychological factors has been shown
to be equally important (Galli, et al., 2017). BMS patients
are interviewed for the presence of underlying psychological
factors using psychological assessment tools, such as State−
Trait Anxiety Inventory, Diagnostic and Statistical Manual
of Mental Disorders or Psychiatry in Primary care (PIPC−
Japan, 2018). The patients are referred to a psychiatrist if
these assessments indicate the presence of a serious underly-
ing psychological disorder. However, most of the BMS pa-
tients have mild stress and anxiety (Galli, et al., 2017). All
the cases in this report presented with mild anxiety, and did
not need to be referred to psychiatrist. They were prescribed
ethyl loflazepate, a potent benzodiazepine, during the first
appointment resulting in a reduction in VAS scores in all 4
patients. Benzodiazepines can reduce anxiety and stress by
acting on the hypothalamus−pituitary−adrenal axis, which
generates pain (Kim & Kho, 2018). In addition, benzodi-
azepines have an anti−hyperalgesic effect (Vuilleumier et al.,
2013). The ethyl loflazepate used in this report may affect
both neuropathic and psychological symptoms of BMS. The
main advantage of ethyl loflazepate is its non−sedative prop-
erty and the long elimination time, thereby reducing the in-
cidence of drug dependence (Fukami et al., 2010). These
findings indicate that ethyl loflazepate can be a considered
as a valid option for the initial treatment of BMS.
Although BMS symptoms were reduced by ethyl loflaze-
pate, the patients complained of residual symptoms. There-
fore, anti − depressants including TCA, SSRI, SNRI, and
NaSSA were prescribed after initial treatment with ethyl lof-
lazepate (Table 1). The patient in case 1 responded very
well to ethyl loflazepate and milnacipran. Milnacipran acts
Case Age/Sex Clinical presentation Drugs used Patient’s response Drug substitution Effective combination of drugs
1 78/F Dull pain in tongue since 4
months, mild anxiety,
VAS=70
Ethyl loflazepate,
Milnacipran
Well tolerated Not required Ethyl loflazepate,
Milnacipran
2 53/F Generalized burning sensa-
tion in tongue, mild anxiety,
VAS=80
Ethyl loflazepate,
Milnacipran, Amitriptyline
Increased heart rate and
blood pressure due to
milnacipran
Milnacipran substituted
with amitriptyline
Ethyl loflazepate,
Amitriptyline
3 72/F Burning sensation in left side
of tongue, mild anxiety,
VAS=90
Ethyl loflazepate,
Milnacipran, Amitriptyline
Ethyl loflazepate and
milnacipran well toler-
ated but no reduction in
pain
Milnacipran substituted
with amitriptyline
Ethyl loflazepate,
Amitriptyline
4 61/F Burning sensation in tongue,
mild anxiety, VAS=76
Ethyl loflazepate,
Venlafaxine, Amitriptyline,
Sertraline, Mirtazapine
Dry mouth due to ami-
triptyline, Nausea due
to sertraline
Amitriptyline substituted
with sertraline, Sertraline
substituted with mirtazap-
ine
Ethyl loflazepate,
venlafaxine and mirtazapine
Table 1 : Clinical presentation and treatment summary of patients
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by inhibiting the reuptake of serotonin and norepinephrine
(Welsch et al., 2018), and has been used for patients with
BMS (Kato et al., 2011). It is considered as a relatively a
safe drug owing to fewer drug interactions and side effects
when compared with TCA (Pae, et al., 2009).
In case 2, milnacipran was used after 3 months of ethyl
loflazepate monotherapy. However, it was discontinued be-
cause the patient complained of increased heart rate and hy-
pertension after taking milnacipran. Milnacipran can also
cause nausea, dizziness, hot flashes, and sweating (Xu et al.,
2016 ) . Amitriptyline was then used in this patient, and
proved effective in reducing the pain. Amitriptyline, a TCA,
is commonly used for the treatment of BMS, and acts
through various mechanisms (Fenelon et al. , 2017) . One
mechanism involves the antagonistic effect on N−methyl−D
−aspartate (NMDA) glutamate receptors, which reduces the
sensitization of second order neurons ( Watanabe et al. ,
1993) . The other mechanism comprises the inhibition of
serotonin, norepinephrine reuptake, and potentiation of endo-
genous opioid, which act on the descending anti−nociceptive
pathway to suppress pain (Dharmshaktu et al. , 2012) . In
some patients, as seen in case 3, milnacipran is well toler-
ated but not effective in reducing pain. Therefore, mil-
nacipran was stopped and substituted with amitriptyline,
which reduced the symptoms in the patient in the current re-
port.
The patient in case 4 had a long history of BMS and did
not respond to ethyl loflazepate. Her stress levels were high
owing to the long duration of the pain. Combination thera-
pies can be effective in patients who do not demonstrate any
reduction in pain after anti − anxiety or anti − depressant
monotherapy ; nonetheless, drug interactions should be taken
into consideration (Moret, 2005 ; Rojo et al., 2005). A com-
bination of venlafaxine and amitriptyline was prescribed in
case 4. Venlafaxine has minimal effect on CYP2D6, and
does not alter amitriptyline levels (Gomez Gomez & Teixido
Perramon, 2000 ) . The symptoms were reduced within 2
months ; however, the patient presented with symptoms of
dry mouth. Amitriptyline is a potent anti−cholinergic drug
and can cause dry mouth (Lawson, 2017). It is also known
to cause sedation, tachycardia, cardiac arrhythmia, seizure
precipitation, and weight gain (Lawson, 2017). Amitriptyline
was substituted with sertraline, a SSRI, which acts by inhib-
iting the reuptake of serotonin into the presynaptic cell and
increasing the amount of serotonin in the synaptic cleft
(Maina et al. , 2002). This can reduce pain, as serotonin
plays a role in nociception and mood regulation, and has
been shown to be effective in the treatment of BMS (Fleuret
et al. , 2014). However, the consumption of sertraline re-
sulted in nausea in the patient, and was therefore replaced
by mirtazapine, a selective serotonin 2, serotonin 3, and α2−
adregenic receptor antagonist. The effects of mirtazapine on
chronic pain associated with psychology have been demon-
strated previously (Arnold et al., 2008 ; Freynhagen et al.,
2006). Eventually, the symptoms had subsided and the con-
dition of the patient was considerably improved. The combi-
nation of ethyl loflazepate, venlafaxine, and mirtazapine
worked best for this patient. Many BMS patients have ad-
mitted that they felt less pain when they had something in
their mouth. We used a thin clear thermoplastic splint cover-
ing the maxillary and mandibular teeth for this purpose in
few patients, as in case 4, which showed good results. The
reduction in pain might be because of a placebo effect and
must be evaluated in future studies.
??????????
The 4 cases presented in this report showed that BMS can
be effectively treated by anti−anxiety and anti−depressant
drugs. The choice of drug can vary from patient to patient,
and the adverse effects of each drug should be well moni-
tored.
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